Compugen Ltd.(CGEN)Earnings, Financials & Key Ratios
CGEN•NASDAQ
5.3× P/E·Price updated Jun 19, 2026
AboutCompugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.Show more
- Revenue$73M+161.1%
- EBITDA$32M+320.8%
- Net Income$35M+348.4%
- EPS (Diluted)0.38+337.5%
- Gross Margin87.29%+22.0%
- EBITDA Margin43.7%+184.5%
- Operating Margin43.05%+180.6%
- Net Margin48.57%+195.1%
- ROE44.84%+289.8%
CGEN Key Insights
Compugen Ltd. (CGEN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong Piotroski F-Score: 7/9
- ✓FCF machine: 43.1% free cash flow margin
- ✓Strong 5Y sales CAGR of 105.2%
✗Weaknesses
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CGEN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CGEN Price & Volume
Compugen Ltd. (CGEN) stock price & volume — 10-year historical chart
Loading chart...
CGEN Growth Metrics
Compugen Ltd. (CGEN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years22.87%
5 Years105.2%
3 Years113.28%
TTM870.19%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM211.99%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM200.93%
Return on Capital
10 Years-34.58%
5 Years-13.55%
3 Years-1%
Last Year27.34%
CGEN Recent Earnings
Compugen Ltd. (CGEN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 4/12 qtrs (36%)
Q2 2026Latest
May 18, 2026Metric
Actual
Est
EPS
$0.08-14.3%
$0.07
Rev
$2M+38.5%
$2M
Q2 2026
Mar 2, 2026Metric
Actual
Est
EPS
$0.60+957.1%
$0.07
Rev
$67M+3018.2%
$2M
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.07+22.2%
$0.09
Rev
$2M-86.8%
$14M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.08-14.3%
$0.07
Rev
$1M-14.5%
$1M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 18, 2026 | $0.08vs $0.07-14.3% | $2Mvs $2M+38.5% |
| Q2 2026 | Mar 2, 2026 | $0.60vs $0.07+957.1% | $67Mvs $2M+3018.2% |
| Q4 2025 | Nov 10, 2025 | $0.07vs $0.09+22.2% | $2Mvs $14M-86.8% |
| Q3 2025 | Aug 6, 2025 | $0.08vs $0.07-14.3% | $1Mvs $1M-14.5% |
Based on last 12 quarters of dataView full earnings history →
CGEN Peer Comparison
Compugen Ltd. (CGEN) competitors in Drug Discovery and Antibody Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RXRX | 1.44B | 3.23 | -2.24 | 26.92% | -8.44% | -54.32% | 0.07 | |
 SDGR | 1.18B | 15.76 | -11.18 | 23.29% | -40.6% | -30.85% | 0.30 | |
 ABSI | 1.16B | 7.41 | -8.82 | -38.24% | -64.51% | -63.58% | 0.03 | |
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 NKTX | 204.62M | 2.86 | -2.03 | -30.9% | 0.24 | |||
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 BCAB | 4.61M | 3.66 | -0.07 | -81.82% | -25.31% | |||
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% |
Compare CGEN vs Peers
Compugen Ltd. (CGEN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CGEN Income Statement
Compugen Ltd. (CGEN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 17.8M | 0 | 2M | 6M | 7.5M | 33.46M | 27.86M | 72.76M |
Revenue Growth % | -100% | - | -100% | - | 200% | 25% | 346.12% | -16.72% | 161.14% |
Cost of Goods Sold | 1.59M | 1.03M | 989K | 60K | 680K | 975K | 2M | 7.93M | 9.25M |
COGS % of Revenue | - | 5.81% | - | 3% | 11.33% | 13% | 5.99% | 28.46% | 12.71% |
Gross Profit | -1.59M▲ 0% | 16.77M▲ 1152.5% | -989K▼ 105.9% | 1.94M▲ 296.2% | 5.32M▲ 174.2% | 6.53M▲ 22.7% | 31.45M▲ 382.1% | 19.93M▼ 36.6% | 63.51M▲ 218.6% |
Gross Margin % | - | 94.19% | - | 97% | 88.67% | 87% | 94.01% | 71.54% | 87.29% |
Gross Profit Growth % | -425.77% | 1152.48% | -105.9% | 296.16% | 174.23% | 22.65% | 382.07% | -36.63% | 218.62% |
Operating Expenses | 37.41M | 39.99M | 28.88M | 33.44M | 40.39M | 41.9M | 44.45M | 34.83M | 32.19M |
OpEx % of Revenue | - | 224.68% | - | 1671.8% | 673.23% | 558.65% | 132.84% | 124.98% | 44.23% |
Selling, General & Admin | 8.82M | 9.68M | 9.06M | 10.68M | 11.7M | 11.25M | 9.97M | 10.02M | 9.43M |
SG&A % of Revenue | - | 54.35% | - | 533.8% | 195% | 150.01% | 29.81% | 35.94% | 12.96% |
Research & Development | 28.58M | 30.32M | 19.82M | 22.76M | 28.69M | 30.65M | 34.47M | 24.81M | 22.76M |
R&D % of Revenue | - | 170.33% | - | 1138% | 478.23% | 408.64% | 103.03% | 89.04% | 31.28% |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -37.41M▲ 0% | -23.23M▲ 37.9% | -28.88M▼ 24.3% | -31.5M▼ 9.1% | -35.07M▼ 11.4% | -35.37M▼ 0.9% | -12.99M▲ 63.3% | -14.89M▼ 14.6% | 31.33M▲ 310.4% |
Operating Margin % | - | -130.49% | - | -1574.8% | -584.57% | -471.65% | -38.83% | -53.44% | 43.05% |
Operating Income Growth % | -14.8% | 37.9% | -24.33% | -9.06% | -11.36% | -0.86% | 63.27% | -14.62% | 310.37% |
EBITDA | -35.81M | -21.83M | -27.89M | -30.78M | -34.61M | -34.89M | -12.52M | -14.4M | 31.8M |
EBITDA Margin % | - | -122.66% | - | -1539.05% | -576.88% | -465.23% | -37.41% | -51.7% | 43.7% |
EBITDA Growth % | -15.15% | 39.03% | -27.74% | -10.37% | -12.45% | -0.81% | 64.13% | -15.09% | 320.76% |
D&A (Non-Cash Add-back) | 1.59M | 1.39M | 989K | 715K | 461K | 482K | 476K | 486K | 475K |
EBIT | -37.05M | -23.23M | -28.03M | -29.66M | -35.07M | -33.61M | -12.99M | -14.89M | 31.33M |
Net Interest Income | 15K | 620K | 903K | 1.72M | 869K | 1.41M | 3.21M | 5.2M | 4.41M |
Interest Income | 523K | 643K | 935K | 1.76M | 894K | 1.44M | 3.24M | 5.24M | 4.41M |
Interest Expense | 508K | 620K | 32K | 42K | 25K | 27K | 31K | 34K | 0 |
Other Income/Expense | 339K | 628K | 820K | 1.8M | 871K | 1.74M | 3.21M | 5.18M | 4.07M |
Pretax Income | -37.07M▲ 0% | -22.6M▲ 39.0% | -28.06M▼ 24.2% | -29.7M▼ 5.8% | -34.2M▼ 15.2% | -33.64M▲ 1.7% | -9.78M▲ 70.9% | -9.71M▲ 0.8% | 35.4M▲ 464.6% |
Pretax Margin % | - | -126.96% | - | -1484.9% | -570.05% | -448.48% | -29.24% | -34.84% | 48.65% |
Income Tax | 0 | 0 | -722K | 0 | 0 | 58K | 8.97M | 4.52M | 54K |
Effective Tax Rate % | 0% | 0% | 2.57% | 0% | 0% | -0.17% | -91.68% | -46.58% | 0.15% |
Net Income | -37.07M▲ 0% | -22.6M▲ 39.0% | -27.34M▼ 21.0% | -29.7M▼ 8.6% | -34.2M▼ 15.2% | -33.69M▲ 1.5% | -18.75M▲ 44.3% | -14.23M▲ 24.1% | 35.34M▲ 348.4% |
Net Margin % | - | -126.96% | - | -1484.9% | -570.05% | -449.25% | -56.05% | -51.07% | 48.57% |
Net Income Growth % | -17.65% | 39.03% | -20.97% | -8.64% | -15.17% | 1.49% | 44.34% | 24.12% | 348.35% |
Net Income (Continuing) | -37.07M | -22.6M | -27.34M | -29.7M | -34.2M | -33.69M | -18.75M | -14.23M | 35.34M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.72▲ 0% | -0.41▲ 43.1% | -0.43▼ 4.9% | -0.37▲ 14.0% | -0.41▼ 10.8% | -0.39▲ 4.9% | -0.21▲ 46.2% | -0.16▲ 23.8% | 0.38▲ 337.5% |
EPS Growth % | -16.13% | 43.06% | -4.88% | 13.95% | -10.81% | 4.88% | 46.15% | 23.81% | 337.5% |
EPS (Basic) | -0.72 | -0.41 | -0.43 | -0.37 | -0.41 | -0.39 | -0.21 | -0.16 | 0.38 |
Diluted Shares Outstanding | 51.18M | 55.28M | 63.64M | 79.59M | 84.2M | 86.56M | 87.63M | 89.53M | 93.82M |
Basic Shares Outstanding | 51.18M | 55.28M | 63.64M | 79.59M | 84.2M | 86.56M | 87.63M | 89.53M | 93.43M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
CGEN Balance Sheet
Compugen Ltd. (CGEN) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 31.18M | 46.58M | 45M | 129.09M | 123.22M | 86.13M | 114.58M | 106M | 148.02M |
Cash & Short-Term Investments | 30.44M | 45.67M | 43.88M | 123.77M | 117.05M | 83.35M | 50.69M | 103.25M | 145.64M |
Cash Only | 30.44M | 45.67M | 9.84M | 7.14M | 7.8M | 11.06M | 13.89M | 18.23M | 90.6M |
Short-Term Investments | 0 | 0 | 34.04M | 116.62M | 109.25M | 72.29M | 36.8M | 85.03M | 55.04M |
Accounts Receivable | 51K | 167K | 341K | 2M | 188K | 317K | 61.32M | 269K | 294K |
Days Sales Outstanding | - | 3.42 | - | 365 | 11.44 | 15.43 | 668.91 | 3.52 | 1.47 |
Inventory | -1.74M | -1.34M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 721K | 713K | 362K | 365K | 0 | 0 |
Total Non-Current Assets | 7.57M | 6.6M | 8.76M | 9.23M | 8.94M | 8.05M | 6.75M | 9M | 8.85M |
Property, Plant & Equipment | 4.65M | 3.37M | 5.58M | 4.48M | 3.9M | 3.36M | 2.54M | 3.69M | 3.2M |
Fixed Asset Turnover | - | 5.28x | - | 0.45x | 1.54x | 2.23x | 13.15x | 7.54x | 22.72x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 410K |
Other Non-Current Assets | 2.92M | 3.23M | 3.18M | 4.74M | 5.04M | 4.69M | 4.21M | 5.3M | 4.94M |
Total Assets | 38.75M▲ 0% | 53.18M▲ 37.3% | 53.76M▲ 1.1% | 138.32M▲ 157.3% | 132.16M▼ 4.4% | 94.18M▼ 28.7% | 121.33M▲ 28.8% | 115M▼ 5.2% | 156.87M▲ 36.4% |
Asset Turnover | - | 0.33x | - | 0.01x | 0.05x | 0.08x | 0.28x | 0.24x | 0.46x |
Asset Growth % | -45.53% | 37.25% | 1.1% | 157.27% | -4.45% | -28.74% | 28.84% | -5.22% | 36.42% |
Total Current Liabilities | 6.19M | 9.99M | 6.82M | 10.52M | 17.1M | 11.92M | 26.27M | 20.16M | 22.57M |
Accounts Payable | 3.44M | 2.95M | 1.09M | 1.41M | 4.62M | 1.77M | 3.5M | 1.84M | 2.35M |
Days Payables Outstanding | 789.34 | 1.04K | 401.54 | 8.6K | 2.48K | 663.74 | 637.84 | 84.6 | 92.84 |
Short-Term Debt | 0 | 0 | 600K | 0 | 0 | 0 | 0 | 0 | 521K |
Deferred Revenue (Current) | 312K | 1.09M | 774K | 0 | 0 | 0 | 11.15M | 9.63M | 10.97M |
Other Current Liabilities | 1.08M | 3.45M | 1.71M | 668K | 6.93M | 3.14M | 3.13M | 3.07M | 5.68M |
Current Ratio | 5.03x | 4.66x | 6.60x | 12.27x | 7.21x | 7.23x | 4.36x | 5.26x | 6.56x |
Quick Ratio | 5.31x | 4.80x | 6.60x | 12.27x | 7.21x | 7.23x | 4.36x | 5.26x | 6.56x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 3.25M | 5.95M | 8.62M | 8.01M | 8.37M | 4.58M | 29.51M | 39.92M | 31.57M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 2.98M | 2.53M | 1.98M | 1.31M | 719K | 2.46M | 2.44M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 303K |
Other Non-Current Liabilities | 3.25M | 2.94M | 2.95M | 5.48M | 6.39M | 3.27M | 3.4M | 3.41M | 3.89M |
Total Liabilities | 9.45M | 15.94M | 15.44M | 18.53M | 25.47M | 16.5M | 55.77M | 60.08M | 54.14M |
Total Debt | 0 | 0 | 3.58M | 3.17M | 2.75M | 1.93M | 1.35M | 2.91M | 2.96M |
Net Debt | -30.44M | -45.67M | -6.26M | -3.98M | -5.05M | -9.13M | -12.54M | -15.32M | -87.64M |
Debt / Equity | - | - | 0.09x | 0.03x | 0.03x | 0.02x | 0.02x | 0.05x | 0.03x |
Debt / EBITDA | - | - | - | - | - | - | - | - | 0.09x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | -2.76x |
Interest Coverage | -72.94x | -37.46x | -875.84x | -706.10x | -1402.96x | -1244.78x | -419.10x | -437.97x | - |
Total Equity | 29.3M▲ 0% | 37.24M▲ 27.1% | 38.32M▲ 2.9% | 119.78M▲ 212.6% | 106.69M▼ 10.9% | 77.68M▼ 27.2% | 65.56M▼ 15.6% | 54.91M▼ 16.2% | 102.73M▲ 87.1% |
Equity Growth % | -53.88% | 27.12% | 2.89% | 212.58% | -10.93% | -27.19% | -15.6% | -16.24% | 87.08% |
Book Value per Share | 0.57 | 0.67 | 0.60 | 1.50 | 1.27 | 0.90 | 0.75 | 0.61 | 1.10 |
Total Shareholders' Equity | 29.3M | 37.24M | 38.32M | 119.78M | 106.69M | 77.68M | 65.56M | 54.91M | 102.73M |
Common Stock | 140K | 164K | 187K | 231K | 239K | 240K | 247K | 248K | 262K |
Retained Earnings | -308.24M | -330.84M | -358.18M | -387.88M | -422.08M | -455.77M | -474.53M | -488.76M | -453.42M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 17K | 0 | 0 | 0 | 0 | 0 | 2K | 11K | 8K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CGEN Cash Flow Statement
Compugen Ltd. (CGEN) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -30.66M | -13.29M | -27.89M | -28.32M | -23.22M | -33.92M | -35.89M | 49.6M | 31.63M |
Operating CF Margin % | - | -74.67% | - | -1416% | -386.98% | -452.29% | -107.25% | 178.02% | 43.47% |
Operating CF Growth % | -54.69% | 56.65% | -109.83% | -1.55% | 18.01% | -46.1% | -5.79% | 238.23% | -36.23% |
Net Income | -37.07M | -22.6M | -27.34M | -29.7M | -34.2M | -33.69M | -18.75M | -14.23M | 35.34M |
Depreciation & Amortization | 1.59M | 1.39M | 989K | 715K | 461K | 482K | 476K | 486K | 475K |
Stock-Based Compensation | 2.63M | 2.17M | 2.41M | 2.77M | 4.28M | 4.33M | 3.55M | 3.02M | 0 |
Deferred Taxes | 0 | 52K | -135K | -12K | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -33K | 46K | -22K | 184K | -573K | 515K | -452K | -1.72M | 1.16M |
Working Capital Changes | 2.21M | 5.65M | -3.79M | -2.28M | 6.82M | -5.55M | -20.71M | 62.05M | -5.35M |
Change in Receivables | 422K | -179K | -142K | -2M | 2M | 3.04M | -61.11M | 59.93M | 360K |
Change in Inventory | 247K | -954K | 3.5M | -3.82M | -3.37M | 0 | 0 | 0 | 0 |
Change in Payables | 1.56M | 2.69M | -3.5M | 3.82M | 3.37M | -1.6M | 3.51M | -4.41M | 517K |
Cash from Investing | 46.27M | -35.16M | 5.33M | -82.17M | 6.62M | 37.06M | 35.51M | -46.25M | 30M |
Capital Expenditures | -385K | -158K | -155K | -166K | -292K | -487K | -172K | -118K | -306K |
CapEx % of Revenue | - | 0.89% | - | 8.3% | 4.87% | 6.49% | 0.51% | 0.42% | 0.42% |
Acquisitions | -46.66M | 2K | 382K | 44K | 3K | 2K | 0 | 0 | 1K |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 46.66M | 2K | 0 | 0 | 0 | 0 | 0 | -329K | 0 |
Cash from Financing | 201K | 28.4M | 25.93M | 108.46M | 16.84M | 353K | 3.08M | 554K | 10.6M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 27.71M | 22.76M | 74.15M | 14.96M | 353K | 3.08M | 544K | 10.61M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 201K | 685K | 3.17M | 34.32M | 1.88M | 0 | 0 | 10K | -4K |
Net Change in Cash | 15.82M▲ 0% | -20.05M▼ 226.8% | 3.37M▲ 116.8% | -2.03M▼ 160.2% | 704K▲ 134.7% | 2.91M▲ 312.9% | 2.83M▼ 2.5% | 3.97M▲ 40.2% | 72.37M▲ 1721.0% |
Free Cash Flow | -31.04M▲ 0% | -13.45M▲ 56.7% | -28.04M▼ 108.5% | -28.49M▼ 1.6% | -23.04M▲ 19.1% | -34.99M▼ 51.9% | -36.06M▼ 3.0% | 49.49M▲ 237.2% | 31.33M▼ 36.7% |
FCF Margin % | - | -75.56% | - | -1424.3% | -384.03% | -466.57% | -107.77% | 177.6% | 43.05% |
FCF Growth % | -38.47% | 56.68% | -108.51% | -1.58% | 19.11% | -51.87% | -3.04% | 237.24% | -36.69% |
FCF per Share | -0.61 | -0.24 | -0.44 | -0.36 | -0.27 | -0.40 | -0.41 | 0.55 | 0.33 |
FCF Conversion (FCF/Net Income) | 0.83x | 0.59x | 1.02x | 0.95x | 0.68x | 1.01x | 1.91x | -3.49x | 0.90x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CGEN Key Ratios
Compugen Ltd. (CGEN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -41.07% | -79.87% | -67.93% | -72.35% | -37.57% | -30.2% | -36.55% | -26.19% | -23.63% | 44.84% |
Return on Invested Capital (ROIC) | -466.89% | -6593.13% | - | -183.34% | -31.95% | -24.19% | -31.18% | -16.03% | -24.12% | 85.92% |
Gross Margin | 68.68% | - | 94.19% | - | 97% | 88.67% | 87% | 94.01% | 71.54% | 87.29% |
Net Margin | -4425% | - | -126.96% | - | -1484.9% | -570.05% | -449.25% | -56.05% | -51.07% | 48.57% |
Debt / Equity | - | - | - | 0.09x | 0.03x | 0.03x | 0.02x | 0.02x | 0.05x | 0.03x |
Interest Coverage | -46.22x | -72.94x | -37.46x | -875.84x | -706.10x | -1402.96x | -1244.78x | -419.10x | -437.97x | - |
FCF Conversion | 0.63x | 0.83x | 0.59x | 1.02x | 0.95x | 0.68x | 1.01x | 1.91x | -3.49x | 0.90x |
Revenue Growth | -92.33% | -100% | - | -100% | - | 200% | 25% | 346.12% | -16.72% | 161.14% |
Related:CGEN Dividend History·CGEN Revenue History·CGEN Price History·CGEN P/E History·CGEN Financial Ratios·CGEN Institutional Holders
CGEN Frequently Asked Questions
Compugen Ltd. (CGEN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Compugen Ltd. (CGEN) reported $72.8M in revenue for fiscal year 2025. This represents a 2148% increase from $3.2M in 1999.
Compugen Ltd. (CGEN) grew revenue by 161.1% over the past year. This is strong growth.
Yes, Compugen Ltd. (CGEN) is profitable, generating $35.3M in net income for fiscal year 2025 (48.6% net margin).
Dividend & Returns
Compugen Ltd. (CGEN) has a return on equity (ROE) of 44.8%. This is excellent, indicating efficient use of shareholder capital.
Compugen Ltd. (CGEN) generated $31.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.